← Back to Screener
Enanta Pharmaceuticals, Inc (ENTA)
Price$13.78
Favorite Metrics
Price vs S&P 500 (26W)18.39%
Price vs S&P 500 (4W)2.50%
Market Capitalization$409.17M
All Metrics
Book Value / Share (Quarterly)$4.36
P/TBV (Annual)0.97x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-8.83%
Cash Flow / Share (Quarterly)$-0.64
Price vs S&P 500 (YTD)-15.30%
Net Profit Margin (TTM)-106.80%
EPS (TTM)$-3.20
10-Day Avg Trading Volume0.11M
EPS Excl Extra (TTM)$-3.20
Revenue Growth (5Y)-11.82%
EPS (Annual)$-3.84
ROI (Annual)-39.39%
Net Profit Margin (5Y Avg)-137.71%
Cash / Share (Quarterly)$6.40
Revenue Growth QoQ (YoY)9.76%
ROA (Last FY)-29.17%
Revenue Growth TTM (YoY)0.58%
EBITD / Share (TTM)$-2.93
ROE (5Y Avg)-67.21%
Operating Margin (TTM)-109.08%
Cash Flow / Share (Annual)$-1.50
P/B Ratio3.23x
P/B Ratio (Quarterly)3.60x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)7.58x
Net Interest Coverage (TTM)12.65x
ROA (TTM)-23.18%
EV / EBITDA (TTM)34.36x
EPS Incl Extra (Annual)$-3.84
Current Ratio (Annual)4.21x
Quick Ratio (Quarterly)4.34x
3-Month Avg Trading Volume0.23M
52-Week Price Return184.18%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$10.29
P/S Ratio (Annual)6.26x
Asset Turnover (Annual)0.23x
52-Week High$17.15
Operating Margin (5Y Avg)-148.06%
EPS Excl Extra (Annual)$-3.84
CapEx CAGR (5Y)54.82%
Tangible BV CAGR (5Y)-11.25%
26-Week Price Return27.13%
Quick Ratio (Annual)4.03x
13-Week Price Return1.23%
Total Debt / Equity (Annual)2.21x
Current Ratio (Quarterly)4.44x
Enterprise Value$507.85
Revenue / Share Growth (5Y)-13.04%
Asset Turnover (TTM)0.22x
Book Value / Share Growth (5Y)-33.15%
Revenue / Employee (Annual)$1
Pretax Margin (Annual)-127.90%
Cash / Share (Annual)$8.83
3-Month Return Std Dev49.01%
Net Income / Employee (TTM)$-1
ROE (Last FY)-126.53%
EPS Basic Excl Extra (Annual)$-3.84
P/FCF (TTM)23.58x
Receivables Turnover (TTM)8.26x
Total Debt / Equity (Quarterly)1.08x
EPS Incl Extra (TTM)$-3.20
Receivables Turnover (Annual)9.66x
ROI (TTM)-30.13%
P/S Ratio (TTM)6.11x
Pretax Margin (5Y Avg)-144.00%
Revenue / Share (Annual)$3.06
Tangible BV / Share (Annual)$10.29
Price vs S&P 500 (52W)149.08%
Year-to-Date Return-11.16%
5-Day Price Return-1.82%
EPS Normalized (Annual)$-3.84
ROA (5Y Avg)-27.87%
Net Profit Margin (Annual)-125.36%
Month-to-Date Return10.93%
Cash Flow / Share (TTM)$-6.26
EBITD / Share (Annual)$-3.79
Operating Margin (Annual)-130.65%
LT Debt / Equity (Annual)1.74x
ROI (5Y Avg)-39.39%
LT Debt / Equity (Quarterly)0.82x
EPS Basic Excl Extra (TTM)$-3.20
P/TBV (Quarterly)0.97x
P/B Ratio (Annual)3.95x
Pretax Margin (TTM)-108.62%
Book Value / Share (Annual)$3.03
Price vs S&P 500 (13W)-1.64%
Beta1.02x
P/FCF (Annual)72.55x
Revenue / Share (TTM)$2.33
ROE (TTM)-78.59%
52-Week Low$4.73
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ENTAEnanta Pharmaceuticals, Inc | 6.11x | 0.58% | — | — | $13.78 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Enanta Pharmaceuticals is a biotechnology company specializing in small-molecule drug discovery for virology and immunology. Its pipeline includes candidates for RSV, SARS-CoV-2, hepatitis B, and type 2 inflammatory disease. The company generates revenue primarily through royalties, including from its collaboration with AbbVie.